These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Occurrence of neoplasms in individuals with congenital, severe GH deficiency from the Itabaianinha kindred.
    Author: Marinho CG, Mermejo LM, Salvatori R, Assirati JA, Oliveira CRP, Santos EG, Leal ÂCGB, Barros-Oliveira CS, Damascena NP, Lima CA, Farias CT, Moreira AC, Aguiar-Oliveira MH.
    Journal: Growth Horm IGF Res; 2018 Aug; 41():71-74. PubMed ID: 29571594.
    Abstract:
    Growth hormone (GH) and the insulin-like growth factor I (IGF-I) have cell proliferative and differentiation properties. Whether these hormones have a role in mutagenesis is unknown. Nevertheless, severe IGF-I deficiency seems to confer protection against the development of neoplasms. Here, we report five cases of adult patients with severe and congenital isolated GH deficiency (IGHD) due to the c.57+1G>A mutation in the GHRH receptor gene, who developed tumors. Four GH-naïve subjects presented skin tumors: a 42-year-old man with a fibroepithelial polyp, a 53-year-old woman and two men (59 and 56 years old) with epidermoid skin cancers. One of these died from it after three surgeries and radiotherapy. The fifth patient was a 25-year-old woman, who had intermittently received GH replacement therapy (GHRT) from age 11 to 18, who developed an ependymoma extending from the fourth ventricle to the end of the thoracic spine. She underwent three surgical procedures, without obvious evidence of tumor recurrence during the six years follow up. These observations suggest that severe IGHD does not protect completely from development of tumors.
    [Abstract] [Full Text] [Related] [New Search]